A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
- A twice-yearly shot has shown 100% effectiveness in preventing HIV infections in women, and similarly high efficacy in men according to a recent study.
- Gilead announced that it will allow affordable, generic versions of the shot in 120 countries with high HIV rates, mainly in Africa, Southeast Asia, and the Caribbean.
- Gilead is trying to establish "fast, efficient pathways to reach all people who need or want lenacapavir for HIV prevention," but availability in Mexico is still uncertain.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left21Leaning Right2Center53Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
69% Center
L 28%
C 69%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
